Nexalin Technology Inc (NXL)

Nexalin Technology First Quarter 2024 Earnings: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023) - Yahoo Finance

Yahoo Finance

Join Nexalin Technology's Exclusive Live Investor Webinar - GlobeNewswire

GlobeNewswire

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23 - Investing.com India

Investing.com India

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23 - Yahoo Canada Finance

Yahoo Canada Finance

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

GlobeNewswire Inc.

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - Yahoo Finance

Yahoo Finance

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Nexalin Ramps Up Manufacturing of Insomnia Neurostimulator Following Successful Testing - Sleep Review

Sleep Review

Nexalin Technology CEO Provides Letter to Shareholders - GlobeNewswire

GlobeNewswire

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and ... - Yahoo Finance

Yahoo Finance

Nexalin Insomnia Neurostimulator Gets Patent for Method of Use - Sleep Review

Sleep Review

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

GlobeNewswire Inc.

Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device - Proactive Investors UK

Proactive Investors UK

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

GlobeNewswire Inc.

Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veterans - Proactive Investors USA

Proactive Investors USA

Healthcare Stocks Moving Monday: XLO, TPST, CNTB, NXL, EIGR, IRON, SRZN, VVOS - InvestorsObserver

InvestorsObserver

Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022) - Yahoo Finance

Yahoo Finance

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain ... - GlobeNewswire

GlobeNewswire

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

GlobeNewswire Inc.

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman ... - GlobeNewswire

GlobeNewswire

Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Nasdaq Gains Over 50 Points; US Economy Adds 275,000 Jobs In February

Benzinga

Neurostimulator Shows Promise in Treating Chronic Insomnia - Sleep Review

Sleep Review

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

GlobeNewswire Inc.

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult ... - GlobeNewswire

GlobeNewswire

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

GlobeNewswire Inc.

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device - Yahoo Finance

Yahoo Finance

Nexalin Technology Unveils Next-Generation HALO™ Clarity - Yahoo Finance

Yahoo Finance

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

GlobeNewswire Inc.

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its ... - Yahoo Finance

Yahoo Finance

Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Benzinga

Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Benzinga

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp ... - GlobeNewswire

GlobeNewswire

Nexalin's CEO Mark White to be Interviewed Live on “The Big - GlobeNewswire

GlobeNewswire

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization ... - Yahoo Finance

Yahoo Finance

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical ... - GlobeNewswire

GlobeNewswire

Nexalin Next-Gen Insomnia Neurostimulator Nears FDA Presentation Stage - Sleep Review

Sleep Review

Nexalin Technology CEO Provides Letter to Shareholders - Yahoo Finance

Yahoo Finance

Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering - GlobeNewswire

GlobeNewswire

Nexalin: Neurostimulation Therapy For Anxiety & Insomnia (NXL) - Seeking Alpha

Seeking Alpha